Reviews Human) Solvent/Detergent Treated


No reviews yet.

BayRab Drug Description
BayRab®
Rabies Immune Globulin (Human) Solvent/Detergent Treated
DRUG DESCRIPTION
Rabies Immune Globulin (Human) — BayRab® treated with solvent/detergent is a sterile solution of antirabies immune globulin for intramuscular administration; it contains no preservative. BayRab is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solu-tion is adjusted to a final concentration of 0.3% tri-n-butyl phosphate ( TNBP) and 0.2% sodium cholate. After the addition of solvent ( TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. BayRab is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine. BayRab is then incubated in the final container for 21–28 days at 20–27°C. The product is standardized against the U.S. Standard Rabies Immune Globulin to contain an average potency value of 150 IU/mL. The U.S. unit of potency is equivalent to the international unit (IU) for rabies antibody.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for BayRab has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1(HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus ( BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 ( Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.Last reviewed on RxList: 10/28/2009




BayRab Drug Description
BayRab®
Rabies Immune Globulin (Human) Solvent/Detergent Treated
DRUG DESCRIPTION
Rabies Immune Globulin (Human) — BayRab® treated with solvent/detergent is a sterile solution of antirabies immune globulin for intramuscular administration; it contains no preservative. BayRab is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solu-tion is adjusted to a final concentration of 0.3% tri-n-butyl phosphate ( TNBP) and 0.2% sodium cholate. After the addition of solvent ( TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. BayRab is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine. BayRab is then incubated in the final container for 21–28 days at 20–27°C. The product is standardized against the U.S. Standard Rabies Immune Globulin to contain an average potency value of 150 IU/mL. The U.S. unit of potency is equivalent to the international unit (IU) for rabies antibody.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for BayRab has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1(HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus ( BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 ( Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.Last reviewed on RxList: 10/28/2009




BayRab Drug Description
BayRab®
Rabies Immune Globulin (Human) Solvent/Detergent Treated
DRUG DESCRIPTION
Rabies Immune Globulin (Human) — BayRab® treated with solvent/detergent is a sterile solution of antirabies immune globulin for intramuscular administration; it contains no preservative. BayRab is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solu-tion is adjusted to a final concentration of 0.3% tri-n-butyl phosphate ( TNBP) and 0.2% sodium cholate. After the addition of solvent ( TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. BayRab is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine. BayRab is then incubated in the final container for 21–28 days at 20–27°C. The product is standardized against the U.S. Standard Rabies Immune Globulin to contain an average potency value of 150 IU/mL. The U.S. unit of potency is equivalent to the international unit (IU) for rabies antibody.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for BayRab has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1(HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus ( BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 ( Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.Last reviewed on RxList: 10/28/2009




BayRab Drug Description
BayRab®
Rabies Immune Globulin (Human) Solvent/Detergent Treated
DRUG DESCRIPTION
Rabies Immune Globulin (Human) — BayRab® treated with solvent/detergent is a sterile solution of antirabies immune globulin for intramuscular administration; it contains no preservative. BayRab is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solu-tion is adjusted to a final concentration of 0.3% tri-n-butyl phosphate ( TNBP) and 0.2% sodium cholate. After the addition of solvent ( TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. BayRab is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine. BayRab is then incubated in the final container for 21–28 days at 20–27°C. The product is standardized against the U.S. Standard Rabies Immune Globulin to contain an average potency value of 150 IU/mL. The U.S. unit of potency is equivalent to the international unit (IU) for rabies antibody.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for BayRab has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1(HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus ( BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 ( Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.Last reviewed on RxList: 10/28/2009




BayRab Drug Description
BayRab®
Rabies Immune Globulin (Human) Solvent/Detergent Treated
DRUG DESCRIPTION
Rabies Immune Globulin (Human) — BayRab® treated with solvent/detergent is a sterile solution of antirabies immune globulin for intramuscular administration; it contains no preservative. BayRab is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solu-tion is adjusted to a final concentration of 0.3% tri-n-butyl phosphate ( TNBP) and 0.2% sodium cholate. After the addition of solvent ( TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. BayRab is formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine. BayRab is then incubated in the final container for 21–28 days at 20–27°C. The product is standardized against the U.S. Standard Rabies Immune Globulin to contain an average potency value of 150 IU/mL. The U.S. unit of potency is equivalent to the international unit (IU) for rabies antibody.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for BayRab has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1(HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus ( BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 ( Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.Last reviewed on RxList: 10/28/2009





Other reviews about Human) Solvent/Detergent Treated on web:

Immune Globulin Intravenous (Human) 5% Solvent/Detergent Treated Octagam® U.S. License No. 1646 Rx only. View this content as a PDF. (62 kb) Description Plasma Network - IGIV (Human) 5% Solvent/Detergent Treated


DESCRIPTION Antihemophilic Factor (Human), Alphanate®, Solvent Detergent / Heat Treated, is a single dose, sterile, lyophilized concentrate of Factor VIII (AHF) intended for ... ANTIHEMOPHILIC FACTOR (HUMAN) ALPHANATE ® Solvent Detergent ...


Alphanate ® Antihemophilic Factor/von Willebrand Factor Complex (Human) Solvent Detergent/ Heat Treated The Power of FVIII/VWF Complex Grifols USA


14-7635-001 (Rev. April 1998) Immune Globulin (Human) BayGam TM Solvent/Detergent Treated DESCRIPTION Immune Globulin (Human) — BayGam TM treated with solvent/detergent is a sterile ... Immune Globulin (Human) BayGamTM Solvent/Detergent Treated


HDCV=human diploid cell vaccine; PCEC=purified chick embryo cell vaccine; RIG ... be totally eliminated. HyperTET™ S/D - Tetanus Immune Globulin (Human) Solvent/Detergent Treated Plasma Network - HyperRAB S/D - Rabies Immune Globulin (Human)


A cluster of serious adverse events, in six (6) patients, occurring at a single institution during orthotopic liver transplantation. PLAS+SD (Pooled Plasma, [Human] Solvent Detergent Treated)


AlphaNine ® SD Coagulation Factor IX (Human) Solvent Detergent Treated/ Virus Filtered The high purity Factor IX you can rely on High purity Factor IX for the prevention and control of ... Grifols USA


Learn about the prescription medication BayRab (Rabies Immune Globulin (Human) Solvent/Detergent Treated), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... BayRab (Rabies Immune Globulin (Human) Solvent/Detergent Treated ...


POOLED PLASMA (HUMAN) SOLVENT DETERGENT TREATED - Boxed warning to indicate new contraindication: PROPOFOL - Contraindication section modified: ROFECOXIB - Reports of gastrointestinal ... WHO Pharmaceuticals Newsletter 2002, No. 03: REGULATORY MATTERS ...


GAMMAGARD S/D Immune Globulin Intravenous (Human) SOLVENT DETERGENT TREATED DESCRIPTION GAMMAGARD S/D,* Immune Globulin Intravenous (Human) [IGIV] is a solvent/detergent treated, sterile ... GAMMAGARD S/D Immune Globulin Intravenous (Human)





Featured Reviews

Reviews Secobarbital Sodium Capsules

Seconal Sodium Drug Description SECONAL SODIUM® (secobarbital sodium) Capsules, USP DRUG DESCRIPTION What are the possible side effects of secobarbital (Seconal Sodium)? Secobarbital may cause a severe allergic reaction. Stop...
Read More  |  Review This
Reviews Proscar

Proscar Drug Description PROSCAR® (finasteride) Tablets DRUG DESCRIPTION What are the possible side effects of finasteride (Propecia, Proscar)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Fluocinolone Acetonide

Derma-Smoothe/FS Drug Description Derma-Smoothe/FS® (fluocinolone acetonide) Topical Oil, 0.01% (Body Oil) For topical use only DRUG DESCRIPTION What are the possible side effects of fluocinolone topical oil (Derma-Smoothe/FS)? Get...
Read More  |  Review This
Reviews Coartem

Coartem Drug Description COARTEM (artemether/lumefantrine) Tablets DRUG DESCRIPTION What are the possible side effects of artemether and lumefantrine (Coartem)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Human Recombinant)

Humulin 70-30 Drug Description HUMULIN® 70/30 (70% human insulin isophane suspension and 30% human insulin) Injection (rDNA ORIGIN) 100 Units per ML (U-100) DRUG DESCRIPTION What are the possible side effects of insulin isophane...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....